Notice: This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OVAS vs. COYA, SGMT, PROC, DERM, BDRX, ORMP, VTYX, GALT, MIST, and IMUXShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), Procaps Group (PROC), Journey Medical (DERM), Biodexa Pharmaceuticals (BDRX), Oramed Pharmaceuticals (ORMP), Ventyx Biosciences (VTYX), Galectin Therapeutics (GALT), Milestone Pharmaceuticals (MIST), and Immunic (IMUX). These companies are all part of the "medical" sector. OvaScience vs. Coya Therapeutics Sagimet Biosciences Procaps Group Journey Medical Biodexa Pharmaceuticals Oramed Pharmaceuticals Ventyx Biosciences Galectin Therapeutics Milestone Pharmaceuticals Immunic Coya Therapeutics (NASDAQ:COYA) and OvaScience (NASDAQ:OVAS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Do institutionals & insiders have more ownership in COYA or OVAS? 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of OvaScience shares are owned by institutional investors. 9.8% of Coya Therapeutics shares are owned by insiders. Comparatively, 7.4% of OvaScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend COYA or OVAS? Coya Therapeutics presently has a consensus price target of $16.25, indicating a potential upside of 145.10%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Coya Therapeutics is more favorable than OvaScience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00OvaScience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, COYA or OVAS? Coya Therapeutics has higher revenue and earnings than OvaScience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$9.55M11.59-$7.99M-$0.65-10.20OvaScience$290K99.66-$50.97MN/AN/A Is COYA or OVAS more profitable? Coya Therapeutics has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. Coya Therapeutics' return on equity of -31.63% beat OvaScience's return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% OvaScience -10,128.37%-47.06%-42.39% Does the MarketBeat Community believe in COYA or OVAS? OvaScience received 254 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 95.24% of users gave Coya Therapeutics an outperform vote while only 63.87% of users gave OvaScience an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2095.24% Underperform Votes14.76%OvaScienceOutperform Votes27463.87% Underperform Votes15536.13% Which has more risk and volatility, COYA or OVAS? Coya Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Does the media prefer COYA or OVAS? In the previous week, Coya Therapeutics had 5 more articles in the media than OvaScience. MarketBeat recorded 5 mentions for Coya Therapeutics and 0 mentions for OvaScience. Coya Therapeutics' average media sentiment score of 0.50 beat OvaScience's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Neutral OvaScience Neutral SummaryCoya Therapeutics beats OvaScience on 13 of the 16 factors compared between the two stocks. Remove Ads Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.90M$6.93B$5.64B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E RatioN/A6.1223.7319.00Price / Sales99.66226.08381.75120.61Price / CashN/A65.6738.0534.64Price / Book0.456.656.904.26Net Income-$50.97M$139.34M$3.18B$247.00M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$0.81+2.4%N/A-76.7%$28.90M$290,000.000.00N/AHigh Trading VolumeCOYACoya Therapeutics1.6341 of 5 stars$6.54-4.9%$16.25+148.5%-31.4%$109.26M$9.55M-10.066Upcoming EarningsAnalyst ForecastNews CoverageSGMTSagimet Biosciences2.823 of 5 stars$3.54-3.8%$23.00+549.7%-38.1%$108.59M$2M0.008Earnings ReportAnalyst ForecastNews CoveragePositive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-70.8%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeDERMJourney Medical2.5218 of 5 stars$5.00-2.7%$9.67+93.3%+52.8%$104.45M$57.77M-5.3290Insider TradeShort Interest ↑News CoverageGap DownBDRXBiodexa Pharmaceuticals1.137 of 5 stars$2.85-6.6%N/AN/A$104.15M$83,000.000.0020Short Interest ↓News CoverageGap DownHigh Trading VolumeORMPOramed Pharmaceuticals1.7031 of 5 stars$2.51-2.3%N/A-10.9%$101.18M$1.34M22.8210VTYXVentyx Biosciences2.8824 of 5 stars$1.42-4.7%$10.00+604.2%-82.2%$101.01MN/A-0.6030Positive NewsGALTGalectin Therapeutics1.0495 of 5 stars$1.59-1.9%$11.00+591.8%-20.4%$99.79MN/A-2.189Gap DownMISTMilestone Pharmaceuticals2.5239 of 5 stars$1.86+1.1%$17.00+814.0%+17.5%$99.19M$1M-2.3030Short Interest ↑High Trading VolumeIMUXImmunic2.7691 of 5 stars$1.09-5.2%$12.67+1,062.1%-23.1%$98.19MN/A-0.8970Upcoming Earnings Remove Ads Related Companies and Tools Related Companies COYA Competitors SGMT Competitors PROC Competitors DERM Competitors BDRX Competitors ORMP Competitors VTYX Competitors GALT Competitors MIST Competitors IMUX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVAS) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
